SAN DIEGO, Sept. 25, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it will be hosting a meeting for analysts and investors on October 2, 2012 in New York. During the meeting, Halozyme's senior management, as well as external advisors to the Company, will provide an update on Halozyme's corporate strategy, pipeline programs and other aspects of the business.
The presentations will be webcast live through the "Investors" section of the Company's website beginning at 10:30 am ET/7:30 am PT am.To access the webcast, please log on to Halozyme's website at www.halozyme.com approximately fifteen minutes prior to the presentation to register and download any necessary audio software. A recording will be made available for 90 days following the event.
About Halozyme Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
Media/Investor Contact: Anne Erickson Executive Director Halozyme Therapeutics 858-704-8264 firstname.lastname@example.org
SOURCE Halozyme Therapeutics, Inc.